Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2015

01.09.2015 | short review

Chronic lymphocytic leukemia: ASH update 2014

verfasst von: MD Michael Steurer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

At the annual meeting of the American Society of Hematology 2014 in San Francisco, a variety of important clinical trials covering topics like first-line immunochemotherapy, maintenance therapy with monoclonal antibodies as well as confirmatory data of novel therapies such as B-cell receptor or BCL2 inhibitors were presented. In view of these data new clinical standards have been set up and validated, respectively. Taken together, the data presented underscores the importance of immunochemotherapy despite the upcoming era of tyrosine kinase inhibitor treatment in chronic lymphocytic leukemia (CLL) as a standard for (ultra-) high-risk patients. Moreover, the concept of response consolidation/maintenance with the use of monoclonal anti-CD20 antibodies as applied for indolent lymphoma may also be clinically relevant for CLL.
Literatur
1.
Zurück zum Zitat Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (ASH Annual Meeting Abstracts). 2014;124:19. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (ASH Annual Meeting Abstracts). 2014;124:19.
2.
Zurück zum Zitat Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts). 2013;122:526. Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts). 2013;122:526.
3.
Zurück zum Zitat Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review an meta-analysis of randomized trials. J Natl Cancer Inst. 2011(23):1799–806. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review an meta-analysis of randomized trials. J Natl Cancer Inst. 2011(23):1799–806.
4.
Zurück zum Zitat Greil R, Obrtlikova P, Smolej L, et al. Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: planned interim analysis of the international randomized AGMT-CLL8/a Mabtenance Trial. Blood (ASH Annual Meeting Abstracts). 2014;124:20. Greil R, Obrtlikova P, Smolej L, et al. Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: planned interim analysis of the international randomized AGMT-CLL8/a Mabtenance Trial. Blood (ASH Annual Meeting Abstracts). 2014;124:20.
5.
Zurück zum Zitat Van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis results. Blood (ASH Annual Meeting Abstracts). 2014;124:21. CrossRef Van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis results. Blood (ASH Annual Meeting Abstracts). 2014;124:21. CrossRef
7.
Zurück zum Zitat O’Brien S, Jones JA, Couture S, et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial. Blood (ASH Annual Meeting Abstracts). 2014;124:327. O’Brien S, Jones JA, Couture S, et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial. Blood (ASH Annual Meeting Abstracts). 2014;124:327.
8.
Zurück zum Zitat Furman R, Sharman JP, Coutre SE, et al. Idelalisib and Rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014, 370(11):997–1007. PubMedCentralCrossRefPubMed Furman R, Sharman JP, Coutre SE, et al. Idelalisib and Rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014, 370(11):997–1007. PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Sharman JP, Coutre SE, Furman R, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Blood (ASH Annual Meeting Abstracts). 2014;124:330. Sharman JP, Coutre SE, Furman R, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Blood (ASH Annual Meeting Abstracts). 2014;124:330.
10.
Zurück zum Zitat Roberts AW, Ma S, Brander DM, et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2014;124:325. Roberts AW, Ma S, Brander DM, et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2014;124:325.
11.
Zurück zum Zitat Finn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-d,g inhibitor, in patients with relapsed/refractory iNHL. Blood (ASH Annual Meeting Abstracts). 2014;124:802. Finn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-d,g inhibitor, in patients with relapsed/refractory iNHL. Blood (ASH Annual Meeting Abstracts). 2014;124:802.
12.
Zurück zum Zitat Jones JA, Geyer S, Andritsos LA, et al. Dinaciclib (SCH 727965) and ofatumumab for the treatment of relapsed and refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): results of a phase 1b/2 study. Blood (ASH Annual Meeting Abstracts). 2014;124:329. CrossRef Jones JA, Geyer S, Andritsos LA, et al. Dinaciclib (SCH 727965) and ofatumumab for the treatment of relapsed and refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): results of a phase 1b/2 study. Blood (ASH Annual Meeting Abstracts). 2014;124:329. CrossRef
13.
Zurück zum Zitat Blocksidge J, Glenn M, Gandhi AK, et al. CC-122 has robust anti-proliferative activity in a primary chronic lymphocytic leukemia (CLL) co-culture model and is superior to lenalidomide. Blood (ASH Annual Meeting Abstracts). 2014;124:4682. Blocksidge J, Glenn M, Gandhi AK, et al. CC-122 has robust anti-proliferative activity in a primary chronic lymphocytic leukemia (CLL) co-culture model and is superior to lenalidomide. Blood (ASH Annual Meeting Abstracts). 2014;124:4682.
Metadaten
Titel
Chronic lymphocytic leukemia: ASH update 2014
verfasst von
MD Michael Steurer
Publikationsdatum
01.09.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0223-7

Weitere Artikel der Ausgabe 3/2015

memo - Magazine of European Medical Oncology 3/2015 Zur Ausgabe